Abstract: The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor that mediates the severe toxicological effects of environmental pollutants such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). CH-223191 is a novel, synthetic small molecule identified through high-throughput screening as a potent and specific AhR antagonist. Unlike naturally occurring AhR antagonists such as flavonoids, CH-223191 exhibits no partial agonist activity and lacks affinity for the estrogen receptor. Pharmacologically, CH-223191 competitively inhibits TCDD binding to the AhR, preventing its nuclear translocation and subsequent DNA binding, thereby suppressing the induction of cytochrome P450 enzymes. In vivo, it effectively protects against TCDD-induced hepatotoxicity, fatty liver, and wasting syndrome. However, recent developmental studies utilizing CH-223191 reveal that basal AhR activity is crucial for embryonic development; pharmacological inhibition of AhR by CH-223191 disrupts the differentiation of embryonic stem cells into cardiomyocytes. While CH-223191 holds significant promise as a chemopreventive agent against dioxin toxicity and as a vital research tool for AhR biology, its potential developmental impacts and the need for long-term safety assessments remain critical areas for future investigation.
1. Introduction
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is a widespread, highly persistent environmental pollutant and one of the most potent man-made toxicants. Exposure to TCDD is associated with a myriad of adverse health effects, including endocrine disruption, reproductive dysfunction, immunotoxicity, liver damage, tumor promotion, and teratogenicity [1]. The majority of these toxic effects are mediated through the activation of the cytosolic aryl hydrocarbon receptor (AhR), a basic helix-loop-helix transcription factor [1]. Upon ligand binding, the AhR translocates to the nucleus, heterodimerizes with the AhR nuclear translocator (ARNT), and binds to dioxin-responsive elements (DREs) to regulate target genes, notably the cytochrome P450 enzymes [1].
Given the central role of AhR in dioxin toxicity, targeting this receptor with small molecule inhibitors is a highly attractive strategy for developing preventive agents. Through the screening of a chemical library containing approximately 10,000 compounds, researchers identified CH-223191 (2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazo-phenyl)-amide) as a novel, potent, and specific AhR antagonist [1]. CH-223191 has since emerged as a critical compound in the fields of toxicology and environmental health, both for its potential to prevent TCDD-associated pathology and as a pharmacological tool to elucidate the physiological roles of AhR in embryonic development [1] [2].
2. Pharmacological Activity
CH-223191 demonstrates significant pharmacological activity both ex vivo and in vivo by counteracting the effects of TCDD. In cultured human hepatoma (HepG2) cells, CH-223191 dose-dependently inhibits TCDD-induced expression of cytochrome P450 1A1 (CYP1A1) mRNA and protein, as well as CYP1A2 and CYP1B1 [1]. It also suppresses TCDD-induced cytochrome P450 enzymatic activity, specifically ethoxyresorufin-O-deethylase (EROD) activity [1].
In vivo, CH-223191 exhibits potent anti-dioxin activity. In mice treated with a lethal dose of TCDD, oral administration of CH-223191 significantly suppressed hepatic CYP1A1 induction by approximately 75% [1]. Furthermore, it prevented TCDD-induced liver toxicity, evidenced by the reduction of elevated plasma aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels, and the suppression of intrahepatocyte fat accumulation (fatty liver) [1]. CH-223191 also successfully prevented TCDD-induced wasting syndrome, allowing mice to maintain normal weight gain compared to the severe weight loss observed in TCDD-only treated cohorts [1].
Beyond toxicology, CH-223191 has been utilized to uncover the physiological role of AhR in development. In embryonic stem (ES) cell models, treatment with CH-223191 significantly decreased the formation of contractile cardiomyocytes [2]. This pharmacological inhibition mirrored the effects of AhR knockdown via shRNA, demonstrating that basal AhR signaling is essential for normal cardiomyogenesis and cardiovascular homeostasis [2].
3. Molecular Mechanism of Action
The primary mechanism of action of CH-223191 is the direct, competitive antagonism of the AhR. Competitive binding assays using cytosolic fractions demonstrate that CH-223191 dose-dependently inhibits the binding of [3H]TCDD to the AhR [1]. By blocking ligand binding, CH-223191 prevents the subsequent steps of AhR activation: it completely inhibits TCDD-mediated nuclear translocation of the AhR and abolishes the receptor's ability to bind to DNA at dioxin-responsive elements (DREs), as confirmed by immunocytochemistry and electrophoretic mobility shift assays [1].
Crucially, CH-223191 acts as a pure antagonist. Unlike many other reported AhR antagonists, it does not exhibit any AhR agonist-like activity even at high concentrations (up to 100 μM) [1]. Additionally, in vitro microsomal assays confirmed that CH-223191 does not directly inactivate cytochrome P450 enzymatic activity; its suppression of CYP450 activity is entirely due to the transcriptional regulation of the AhR [1]. Furthermore, CH-223191 has no effect on estrogen receptor-mediated transcription, ensuring it does not possess estrogenic potency [1].
4. Structure-Activity Relationship (SAR)
While an exhaustive structure-activity relationship study is not detailed in the provided literature, the structural properties of CH-223191 (a synthetic pyrazole-carboxamide derivative) provide a distinct pharmacological profile compared to naturally occurring AhR antagonists. Historically, compounds such as flavone, resveratrol, and α-naphthoflavone have been identified as AhR antagonists. However, these flavonoid and stilbene derivatives frequently display concentration-dependent AhR agonist activity, leading to increased CYP450 expression at higher doses [1]. Moreover, many of these natural compounds possess a high affinity for the estrogen receptor, which can stimulate the proliferation of human breast cancer cells and pose estrogen-related risks [1]. The unique synthetic structure of CH-223191 circumvents these issues, providing high-affinity competitive antagonism of the AhR without triggering agonist-induced conformational changes or interacting with estrogen-responsive elements [1].
5. Current Limitations
Despite its potent protective effects against dioxin toxicity, the current understanding of CH-223191 has several limitations. First, the evidence demonstrating that CH-223191 is non-toxic in vivo is preliminary and restricted to short-term outcomes [1]. For any potential medical or chemopreventive application, comprehensive safety assessments are mandatory. These must include genotoxicity assays, chronic toxicity studies, and lifetime carcinogenicity assays, alongside a full understanding of its pharmacokinetics [1].
Secondly, developmental toxicity is a significant concern. Research indicates that the AhR plays a master regulatory role in embryonic development, particularly in coordinating the complex regulatory network required for cardiovascular homeostasis [2]. Because pharmacological inhibition of AhR by CH-223191 disrupts the expression of homeobox transcription factors and halts cardiomyocyte differentiation in embryonic stem cells, systemic administration of CH-223191 during pregnancy could potentially induce severe developmental defects or congenital heart anomalies [2]. Therefore, its use must be strictly controlled regarding developmental timing.
6. Future Perspectives
CH-223191 represents a highly valuable compound for both therapeutic development and basic research. Clinically, it holds promise as a specific chemopreventive agent to mitigate the toxic and carcinogenic effects of accidental or occupational exposure to dioxins and related environmental pollutants [1]. Its lack of estrogenic activity and pure antagonistic profile make it a superior candidate compared to previously identified natural AhR modulators [1].
In the realm of basic science, CH-223191 is an indispensable tool for dissecting AhR-mediated signal transduction. It allows researchers to separate the toxicological responses of exogenous AhR activation (e.g., by TCDD) from the physiological, endogenous functions of the AhR [2]. Future studies utilizing CH-223191 will likely focus on uncovering the endogenous ligands of the AhR and further mapping the receptor's critical role in stem cell pluripotency, organogenesis, and tissue homeostasis [2].
